DB16432InvestigationalVaccines
MVA-SARS-2-S is a COVID-19 vaccine candidate that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein . MVA is a highly attenuated poxvirus vector that has... MVA is a highly attenuated poxvirus vector that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts and is used to develop vaccines for infectious diseases...
- Code names
- MVA-SARS-2-S
What you can answer from here — as of January 16, 2021
Which companies are running trials of MVA-SARS-2-S, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account